Pandemics

DETAILED DESCRIPTION OF DALLAS HOPSITAL'S LEARNING ON THE FLY TO COPE WITH ITS FIRST EBOLA PATIENT.

THE WASHINGTON POST           Oct. 15, 2014
By Amy Ellis Nutt, Abby Phillip and Joel Achenbach

DALLAS — The hospital that treated Ebola victim Thomas Eric Duncan had to learn on the fly how to control the deadly virus, adding new layers of protective gearfor workers in what became a losing battle to keep the contagion from spreading, a top official with the Centers for Disease Control and Prevention said Tuesday.

“They kept adding more protective equipment as the patient [Duncan] deteriorated. They had masks first, then face shields, then the positive-pressure respirator. They added a second pair of gloves,” said Pierre Rollin, a CDC epidemiologist.

FIERCE BOIOTECH RESEARCH                       Oct. 14, 2014
By Emily Mullin

Before the current Ebola outbreak, the virus had only appeared in Africa in fits and starts since its discovery in 1976, receding back into the jungle almost as quickly as it arrived. This relative rarity and the swiftness with which the disease kills its victims has, up until now, made Ebola an unattractive--not to mention daunting--prospect for drug developers. As a result, no approved drugs or vaccines against Ebola exist.

...the current situation in West Africa... has prompted the World Health Organization to call on international government agencies and the pharmaceutical industry to work together to speed up the development of promising therapies for experimental use for those most at risk of contracting the disease, which causes severe hemorrhagic fever.

Now, a handful of players are racing to get a treatment or vaccine to patients as quickly as possible, even though these drugs remain largely untested in humans.... 

Here is a list of organizations that are in the global spotlight right now with their investigational Ebola program

See full story and list

WASHINGTON POST

By Todd C. Frankel                         October 14

....The Dallas nurse, 26-year old Nina Pham,who helped treat Thomas Eric Duncan, the Liberian man who was the first person diagnosed with the dreaded disease in the United States became the first – and so far only – person infected by Duncan. In the wake of her infection, U.S. health officials have pledged to review how future Ebola cases are handled.

But the case is also noteworthy for another, potentially positive reason: Nearly 50 people were exposed to Ebola before the nurse, and none of them has been diagnosed with the disease.

This group of neighbors, family members and first responders are being watched carefully by health authorities. They had some degree of close contact with Duncan during the four-day period when he was contagious – from when he started showing Ebola symptoms on Sept. 24 to when the hospital finally admitted him on Sept. 28. They didn’t take any Ebola-specific precautions. They didn’t know he was infected.... Yet, so far, they have not gotten sick. And their 21-day Ebola incubation period started before Pham’s.

HUFFINGTON POST

By Sam Stein                                                              Updated Oct. 13 ,2014

BETHESDA, Md. -- As the federal government frantically works to combat the Ebola outbreak in West Africa, and as it responds to a second diagnosis of the disease at home, one of the country's top health officials says a vaccine likely would have already been discovered were it not for budget cuts.

Dr. Francis Collins, the head of the National Institutes of Health, said that a decade of stagnant spending has "slowed down" research on all items, including vaccinations for infectious diseases. As a result, he said, the international community has been left playing catch-up on a potentially avoidable humanitarian catastrophe.

"NIH has been working on Ebola vaccines since 2001. It's not like we suddenly woke up and thought, 'Oh my gosh, we should have something ready here,'" Collins told The Huffington Post on Friday. "Frankly, if we had not gone through our 10-year slide in research support, we probably would have had a vaccine in time for this that would've gone through clinical trials and would have been ready."